Syndax Pharmaceuticals Inc Balance Sheet
SNDX / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 12 fiscal years. All figures from audited SEC 10-K filings.
Syndax Pharmaceuticals Inc had $530M in total assets and $65M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $134.9M | $154.1M | $295.4M | $74.4M | $115.2M | $24.6M | $33.8M | $35.2M | $23.8M | $10.0M | $23.2M | $10.0M |
| Accounts Receivable | $38.0M | $7.6M | $0 | - | - | - | - | - | - | - | - | - |
| Inventory | $32.8M | $366.0K | $0 | - | - | - | - | - | - | - | - | - |
| Current Assets | $528.1M | $603.1M | $580.9M | $489.8M | $448.4M | $298.9M | $62.3M | $83.3M | $133.4M | $108.5M | $88.0M | - |
| PP&E (Net) | $181.0K | $0 | $8.0K | $20.0K | $278.0K | $192.0K | $281.0K | $373.0K | $267.0K | $260.0K | $88.0K | - |
| Total Assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M | $300.6M | $63.5M | $83.9M | $137.2M | $109.0M | $89.9M | - |
| Current Liabilities | $120.1M | $103.5M | $58.1M | $29.1M | $20.7M | $18.9M | $18.4M | $16.1M | $15.8M | $10.4M | $4.8M | - |
| Shareholders' Equity | $64.6M | $288.1M | $554.2M | $467.4M | $31.6M | $53.0M | $104.3M | $84.1M | -$252.4M | -$152.6M | -$252.4M | -$152.6M |